The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) consortium was a collaborative research initiative aiming to improve the understanding, diagnosis and management of AD through the utilisation of ß-amyloid PET imaging. AMYPAD was funded by the Innovative Medicines Institute (now known as the Innovative Health Initiative) for a period of 6 years, until 30 September 2022. AMYPAD was selected for publication in the “Results in Brief” section of the European Commission’s CORDIS website.
The article includes some insights that emerged during the project and highlights the collaborative work between academic and industrial partners. “We have had a very fruitful partnership between the industry and academic partners and we are very proud that both of these large clinical studies were completed within the project timeframe and are now yielding results that could directly impact patients in the clinic,” says Gill Farrar, EFPIA lead for the project. While the project may be finished, the consortium’s work continues. The AMYPAD dataset of over 3.500 amyloid PET scans covering the entire Alzheimer’s disease continuum will become available to the global research community soon.
“We are finalising procedures to further unlock the wealth of the data we generated. We hope that the AMYPAD data will be a significant asset to worldwide research in the dementia field.”, says Frederik Barkhof, AMYPAD project coordinator. You can read the article published on the CORDIS website here: